HLA-Restricted Neoantigen Peptides From Common Cancer Mutations
Identification of HLA class II-restricted T cell epitopes in public neoantigens from common cancer mutations enables shared peptide vaccines applicable to multiple patients.
Quick Facts
What This Study Found
Identification of HLA class II-restricted T cell epitopes in public neoantigens from common cancer mutations enables shared peptide vaccines applicable to multiple patients.
Key Numbers
Study focused on ESR1 and PIK3CA mutations — two of the most common genetic changes in hormone receptor-positive breast cancer.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Identification of HLA class II-restricted T cell epitopes in public neoantigens from common cancer m
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer.
- Published In:
- BMC cancer, 25(1), 610 (2025)
- Authors:
- Ando, Yukari, Miyadera, Hiroko, Bando, Hiroko, Hashimoto, Sachie, Noguchi, Emiko, Hara, Hisato
- Database ID:
- RPEP-09943
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Identification of HLA class II-restricted T cell epitopes in public neoantigens from common cancer mutations enables shared peptide vaccines applicable to multiple patients.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09943APA
Ando, Yukari; Miyadera, Hiroko; Bando, Hiroko; Hashimoto, Sachie; Noguchi, Emiko; Hara, Hisato. (2025). HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer.. BMC cancer, 25(1), 610. https://doi.org/10.1186/s12885-025-13992-6
MLA
Ando, Yukari, et al. "HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer.." BMC cancer, 2025. https://doi.org/10.1186/s12885-025-13992-6
RethinkPeptides
RethinkPeptides Research Database. "HLA class II-restricted T cell epitopes in public neoantigen..." RPEP-09943. Retrieved from https://rethinkpeptides.com/research/ando-2025-hla-class-iirestricted-t
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.